Concomitant BRAF and PI3K/mTOR Blockade Is Required for Effective Treatment of BRAFV600E Colorectal Cancer

Purpose: BRAFV600E mutations are associated with poor clinical prognosis in colorectal cancer (CRC). Although selective BRAF inhibitors are effective for treatment of melanoma, comparable efforts in CRC have been disappointing. Here, we investigated potential mechanisms underlying this resistance to BRAF inhibitors in BRAFV600E CRC. Experimental Design: We examined phosphoinositide 3-kinase (PI3K)/mTOR signaling in BRAFV600E CRC cell lines after BRAF inhibition and cell viability and apoptosis after combined BRAF and PI3K/mTOR inhibition. We assessed the efficacy of in vivo combination treatment using a novel genetically engineered mouse model (GEMM) for BRAFV600E CRC. Results: Western blot analysis revealed sustained PI3K/mTOR signaling upon BRAF inhibition. Our BRAFV600E GEMM presented with sessile serrated adenomas/polyps, as seen in humans. Combination treatment in vivo resulted in induction of apoptosis and tumor regression. Conclusions: We have established a novel GEMM to interrogate BRAFV600E CRC biology and identify more efficacious treatment strategies. Combination BRAF and PI3K/mTOR inhibitor treatment should be explored in clinical trials. Clin Cancer Res; 19(10); 2688–98. ©2013 AACR.

[1]  Michael A. Davies,et al.  Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents , 2012, Clinical Cancer Research.

[2]  Sabine Tejpar,et al.  A robust genomic signature for the detection of colorectal cancer patients with microsatellite instability phenotype and high mutation frequency# , 2012, The Journal of pathology.

[3]  Mari Mino-Kenudson,et al.  EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. , 2012, Cancer discovery.

[4]  Qiongqing Wang,et al.  Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation. , 2012, Cancer research.

[5]  S. Kopetz,et al.  Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. , 2012, Cancer research.

[6]  R. Bernards,et al.  Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR , 2012, Nature.

[7]  Erin M. Coffee,et al.  The Dual PI3K/mTOR Inhibitor NVP-BEZ235 Induces Tumor Regression in a Genetically Engineered Mouse Model of PIK3CA Wild-Type Colorectal Cancer , 2011, PloS one.

[8]  B. Nelkin,et al.  Synergistic Action of a RAF Inhibitor and a Dual PI3K/mTOR Inhibitor in Thyroid Cancer , 2011, Clinical Cancer Research.

[9]  A. Ribas,et al.  Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition. , 2011, Cancer research.

[10]  K. Flaherty,et al.  BRAF targeted therapy changes the treatment paradigm in melanoma , 2011, Nature Reviews Clinical Oncology.

[11]  A. Hauschild,et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[12]  L. Andĕra,et al.  Selective BRAFV600E Inhibitor PLX4720, Requires TRAIL Assistance to Overcome Oncogenic PIK3CA Resistance , 2011, PloS one.

[13]  J. Meyerhardt,et al.  Phosphorylated AKT expression is associated with PIK3CA mutation, low stage, and favorable outcome in 717 colorectal cancers , 2011, Cancer.

[14]  N. Rosen,et al.  Resistance to BRAF inhibition in melanomas. , 2011, The New England journal of medicine.

[15]  Y. Oda,et al.  Sessile Serrated Adenoma With Early Neoplastic Progression: A Clinicopathologic and Molecular Study , 2011, The American journal of surgical pathology.

[16]  S. Nelson,et al.  Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation , 2010, Nature.

[17]  C. Der.  Faculty Opinions recommendation of COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. , 2010 .

[18]  Damien Kee,et al.  Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. , 2010, Cancer cell.

[19]  M. Herlyn,et al.  PLX4032, a potent inhibitor of the B‐Raf V600E oncogene, selectively inhibits V600E‐positive melanomas , 2010, Pigment cell & melanoma research.

[20]  P. Hersey,et al.  MEK-Independent Survival of B-RAFV600E Melanoma Cells Selected for Resistance to Apoptosis Induced by the RAF Inhibitor PLX4720 , 2010, Clinical Cancer Research.

[21]  S. Cook,et al.  V600EBraf induces gastrointestinal crypt senescence and promotes tumour progression through enhanced CpG methylation of p16INK4a , 2010, EMBO molecular medicine.

[22]  Kam Y. J. Zhang,et al.  Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma , 2010, Nature.

[23]  J. Dering,et al.  Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma. , 2010, Neoplasia.

[24]  K. Batts,et al.  Serrated Colorectal Neoplasia. , 2010, Surgical pathology clinics.

[25]  M. Tzardi,et al.  BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients’ outcome , 2010, British Journal of Cancer.

[26]  A. Batistatou,et al.  Molecular basis of colorectal cancer. , 2010, The New England journal of medicine.

[27]  M. Belvin,et al.  RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth , 2010, Nature.

[28]  Sabine Tejpar,et al.  Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Umar Mahmood,et al.  Development of a mouse model for sporadic and metastatic colon tumors and its use in assessing drug treatment , 2010, Proceedings of the National Academy of Sciences.

[30]  K. Kinzler,et al.  Glucose Deprivation Contributes to the Development of KRAS Pathway Mutations in Tumor Cells , 2009, Science.

[31]  A. Burgess,et al.  Selective inhibition of proliferation in colorectal carcinoma cell lines expressing mutant APC or activated B‐Raf , 2009, International journal of cancer.

[32]  J. Meyerhardt,et al.  Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer , 2009, British Journal of Cancer.

[33]  M. Belvin,et al.  Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression. , 2009, Cancer research.

[34]  Ralph Weissleder,et al.  Effective Use of PI3K and MEK Inhibitors to Treat Mutant K-Ras G12D and PIK3CA H1047R Murine Lung Cancers , 2008, Nature Medicine.

[35]  P. Pandolfi,et al.  Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. , 2008, The Journal of clinical investigation.

[36]  W. Gerald,et al.  Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. , 2008, The Journal of clinical investigation.

[37]  Daniela Gabriel,et al.  Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity , 2008, Molecular Cancer Therapeutics.

[38]  Kam Y. J. Zhang,et al.  Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity , 2008, Proceedings of the National Academy of Sciences.

[39]  M. Serrano,et al.  A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. , 2007, Genes & development.

[40]  Ji Luo,et al.  The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism , 2006, Nature Reviews Genetics.

[41]  Jennifer J. Lund,et al.  Adenomatous Polyposis Coli (APC) Is Required for Normal Development of Skin and Thymus , 2006, PLoS genetics.

[42]  R. Halberg,et al.  Use of mononucleotide repeat markers for detection of microsatellite instability in mouse tumors , 2005, Molecular carcinogenesis.

[43]  R. Wolff,et al.  Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. , 2005, Cancer research.

[44]  D. Tuveson,et al.  Suppression of BRAF(V599E) in human melanoma abrogates transformation. , 2003, Cancer research.

[45]  M. Barbacid,et al.  RAS oncogenes: the first 30 years , 2003, Nature Reviews Cancer.

[46]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[47]  D. Snover.  Update on the serrated pathway to colorectal carcinoma. , 2011, Human pathology.

[48]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[49]  S. Cook,et al.  V600E Braf induces gastrointestinal crypt senescence and promotes tumour progression through enhanced CpG , 2010 .